-
M23 militia says to pull out of key DR Congo city at US's request
-
Thousands of glaciers to melt each year by mid-century: study
-
China to impose anti-dumping duties on EU pork for five years
-
Nepal starts tiger census to track recovery
-
Economic losses from natural disasters down by a third in 2025: Swiss Re
-
Indonesians reeling from flood devastation plea for global help
-
Timeline: How the Bondi Beach mass shooting unfolded
-
On the campaign trail in a tug-of-war Myanmar town
-
Bondi Beach suspect visited Philippines on Indian passport
-
Kenyan girls still afflicted by genital mutilation years after ban
-
Djokovic to warm up for Australian Open in Adelaide
-
Man bailed for fire protest on track at Hong Kong's richest horse race
-
Men's ATP tennis to apply extreme heat rule from 2026
-
10-year-old girl, Holocaust survivors among Bondi Beach dead
-
Steelers edge towards NFL playoffs as Dolphins eliminated
-
Australian PM says 'Islamic State ideology' drove Bondi Beach gunmen
-
Canada plow-maker can't clear path through Trump tariffs
-
Bank of Japan expected to hike rates to 30-year high
-
Cunningham leads Pistons past Celtics
-
Stokes tells England to 'show a bit of dog' in must-win Adelaide Test
-
EU to unveil plan to tackle housing crisis
-
EU set to scrap 2035 combustion-engine ban in car industry boost
-
Australian PM visits Bondi Beach hero in hospital
-
'Easiest scam in the world': Musicians sound alarm over AI impersonators
-
'Waiting to die': the dirty business of recycling in Vietnam
-
Asian markets retreat ahead of US jobs as tech worries weigh
-
Famed Jerusalem stone still sells despite West Bank economic woes
-
Trump sues BBC for $10 billion over documentary speech edit
-
Chile follows Latin American neighbors in lurching right
-
Will OpenAI be the next tech giant or next Netscape?
-
Khawaja left out as Australia's Cummins, Lyon back for 3rd Ashes Test
-
Australia PM says 'Islamic State ideology' drove Bondi Beach shooters
-
Scheffler wins fourth straight PGA Tour Player of the Year
-
New APAC Partnership with Matter Brings Market Logic Software's Always-On Insights Solutions to Local Brand and Experience Leaders
-
Security beefed up for Ashes Test after Bondi shooting
-
Wembanyama blocking Knicks path in NBA Cup final
-
Amorim seeks clinical Man Utd after 'crazy' Bournemouth clash
-
Man Utd blow lead three times in 4-4 Bournemouth thriller
-
Stokes calls on England to 'show a bit of dog' in must-win Adelaide Test
-
Trump 'considering' push to reclassify marijuana as less dangerous
-
Chiefs coach Reid backing Mahomes recovery after knee injury
-
Trump says Ukraine deal close, Europe proposes peace force
-
French minister urges angry farmers to trust cow culls, vaccines
-
Angelina Jolie reveals mastectomy scars in Time France magazine
-
Paris Olympics, Paralympics 'net cost' drops to 2.8bn euros: think tank
-
Chile president-elect dials down right-wing rhetoric, vows unity
-
Five Rob Reiner films that rocked, romanced and riveted
-
Rob Reiner: Hollywood giant and political activist
-
Observers say Honduran election fair, but urge faster count
-
Europe proposes Ukraine peace force as Zelensky hails 'real progress' with US
Pfizer completes Metsera acquisition in deal worth up to $10 bn
US drugmaker Pfizer said Thursday that it has completed its acquisition of biotech firm Metsera, closing a deal worth up to $10 billion after a fierce bidding war.
The approval from Metsera's shareholders opens the door for Pfizer to make inroads into the fast-growing market for weight loss drugs.
Metsera, a US company specializing in obesity treatments, had been the subject of escalating offers from Pfizer and Danish challenger Novo Nordisk, which makes the weight loss drug Wegovy and Ozempic, a diabetes medication with weight loss benefits.
Pfizer said in a statement that its acquisition was successfully completed.
It had offered to acquire Metsera for up to $86.25 per share, making the deal worth around $10 billion.
This involved $65.60 per share in cash, and an additional $20.65 per share linked to the success of its drug pipeline.
"By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth therapeutic areas and positioning ourselves to define it," said Pfizer chief executive Albert Bourla.
"We look forward to combining Metsera's innovative portfolio with our global development, manufacturing and commercial infrastructure," he added.
The potential sale of Metsera to Novo Nordisk had drawn scrutiny over potential antitrust implications.
F.Ferraz--PC